- Home
- NAUT vs MCRB Comparison
NAUT vs MCRB Comparison
Compare NAUT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- MCRB
- Stock Information
- Founded
- NAUT 2016
- MCRB 2010
- Country
- NAUT United States
- MCRB United States
- Employees
- NAUT N/A
- MCRB N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- MCRB Health Care
- Exchange
- NAUT Nasdaq
- MCRB Nasdaq
- Market Cap
- NAUT 91.5M
- MCRB 103.7M
- IPO Year
- NAUT N/A
- MCRB 2015
- Fundamental
- Price
- NAUT $0.77
- MCRB $12.09
- Analyst Decision
- NAUT Strong Sell
- MCRB Hold
- Analyst Count
- NAUT 1
- MCRB 4
- Target Price
- NAUT $1.75
- MCRB $73.67
- AVG Volume (30 Days)
- NAUT 561.4K
- MCRB 107.4K
- Earning Date
- NAUT 07-29-2025
- MCRB 08-12-2025
- Dividend Yield
- NAUT N/A
- MCRB N/A
- EPS Growth
- NAUT N/A
- MCRB N/A
- EPS
- NAUT N/A
- MCRB 8.98
- Revenue
- NAUT N/A
- MCRB N/A
- Revenue This Year
- NAUT N/A
- MCRB N/A
- Revenue Next Year
- NAUT N/A
- MCRB N/A
- P/E Ratio
- NAUT N/A
- MCRB $1.42
- Revenue Growth
- NAUT N/A
- MCRB N/A
- 52 Week Low
- NAUT $0.66
- MCRB $6.53
- 52 Week High
- NAUT $3.09
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- NAUT 51.04
- MCRB 66.74
- Support Level
- NAUT $0.69
- MCRB $10.67
- Resistance Level
- NAUT $0.82
- MCRB $12.84
- Average True Range (ATR)
- NAUT 0.06
- MCRB 1.09
- MACD
- NAUT 0.00
- MCRB 0.34
- Stochastic Oscillator
- NAUT 50.00
- MCRB 85.98
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.